Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of WXFL10203614 tablets in moderate to severe active ulcerative colitis
CTR20242142Phase 2Active
- Sponsor
- Wuxi Fortune Pharmaceutical Co., Ltd.
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of WXFL10203614 in autoimmune colitis, sponsored by Wuxi Fortune Pharmaceutical Co., Ltd. Started Sep 2024; status: active.
02
Drugs
WXFL10203614
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20242142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242142.